Group Leader, Vaccine Formulation and Adjuvants
- Jenner Investigator
- Head of VFI-Oxford Adjuvant Programme
- Jenner Institute Director of Graduate Studies
- Jenner Institute Lead for Public Engagement
Anita Milicic studied Molecular Biology and Physiology at the University of Belgrade, Serbia, before completing MSc in Genetics and DPhil in Immunology at the University of Oxford. In 2009 she joined the Jenner Institute in Oxford as the Head of the Adjuvant Facility, procuring and testing a range of novel vaccine adjuvants for human and veterinary application.
Anita now leads the Vaccine Formulation and Adjuvants Group, exploring immune mechanisms of vaccines and adjuvants and developing novel vaccine formulations and delivery modalities. Her research interest is in understanding the processes that underpin the immune response to vaccination, in particular the interplay between innate and adaptive immunity. This is studied through modulating the context (i.e. vaccine platform) and kinetics (bolus, continuous) of vaccine antigen delivery, employing a combination of in vitro and in vivo animal model systems and human in vitro and ex vivo studies.
Apart from research, Anita is involved in teaching at Oxford and externally (Milicic, A., Vaccination [Video file], Henry Stewart Talks: The Biomedical & Life Sciences Collection, 2021) and writing popular science articles on vaccination and vaccine adjuvants.
Anita is the Jenner Institute Director of Graduate Studies and the Lead for Public Engagement with Research.
Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.
Reinke S. et al, (2023), Cell reports. Medicine
Adjuvants, immunomodulators, and adaptogens
Milicic A. et al, (2022), Vaccinology and Methods in Vaccine Research, 223 - 280
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases.
Luchner M. et al, (2021), Pharmaceutics, 13
Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology
Codd AS. et al, (2021), Oxford Open Immunology, 2
T cell phenotypes in COVID-19 - a living review
Hanna SJ. et al, (2021), Oxford Open Immunology, 2
The role and uses of antibodies in COVID-19 infections: a living review
Scourfield DO. et al, (2021), Oxford Open Immunology, 2
Development of a delayed burst delivery system for single dose vaccination
Guyon R. et al, (2021), EUROPEAN JOURNAL OF IMMUNOLOGY, 51, 408 - 408
Mucosal immune responses in COVID19 - a living review.
Pearson CF. et al, (2021), Oxf Open Immunol, 2